Literature DB >> 30916794

Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain.

Marcus A Carden1, David C Brousseau2, Fahd A Ahmad3, Jonathan Bennett4, Seema Bhatt5, Amanda Bogie6, Kathleen Brown7, Theron Charles Casper8, Laura L Chapman9, Corrie E Chumpitazi10, Daniel Cohen11, Carlton Dampier12,13, Angela M Ellison14, Hartmut Grasemann15, Robert W Hickey16, Lewis L Hsu17, Sara Leibovich18, Elizabeth Powell19, Rachel Richards8, Syana Sarnaik20, Debra L Weiner21, Claudia R Morris22,23.   

Abstract

Vaso-occlusive pain events (VOE) are the leading cause of emergency department (ED) visits in sickle cell anemia (SCA). This study assessed the variability in use of intravenous fluids (IVFs), and the association of normal saline bolus (NSB), on pain and other clinical outcomes in children with SCA, presenting to pediatric emergency departments (PED) with VOE. Four-hundred charts of children age 3-21 years with SCA/VOE receiving parenteral opioids at 20 high-volume PEDs were evaluated in a retrospective study. Data on type and amount of IVFs used were collected. Patients were divided into two groups: those who received NSB and those who did not. The association of NSB use on change in pain scores and admission rates was evaluated. Among 400 children studied, 261 (65%) received a NSB. Mean age was 13.8 ± 4.9 years; 46% were male; 92% had hemoglobin-SS. The IVFs (bolus and/or maintenance) were used in 84% of patients. Eight different types of IVFs were utilized and IVF volume administered varied widely. Mean triage pain scores were similar between groups, but improvement in pain scores from presentation-to-ED-disposition was smaller in the NSB group (2.2 vs 3.0, P = .03), while admission rates were higher (71% vs 59%, P = .01). Use of NSB remained associated with poorer final pain scores and worse change in pain scores in our multivariable model. In conclusion, wide variations in practice utilizing IVFs are common. NSB is given to >50% of children with SCA/VOE, but is associated with poorer pain control; a controlled prospective trial is needed to determine causality.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Pediatric Emergency Care Applied Research Network (PECARN); emergency department; normal saline bolus; sickle cell anemia; vaso-occlusive pain

Mesh:

Substances:

Year:  2019        PMID: 30916794      PMCID: PMC6510594          DOI: 10.1002/ajh.25471

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  29 in total

Review 1.  Sickle cell biomechanics.

Authors:  Gilda A Barabino; Manu O Platt; Dhananjay K Kaul
Journal:  Annu Rev Biomed Eng       Date:  2010-08-15       Impact factor: 9.590

Review 2.  Fluid replacement therapy for acute episodes of pain in people with sickle cell disease.

Authors:  U Okomo; M M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

3.  Guideline on the management of acute chest syndrome in sickle cell disease.

Authors:  Jo Howard; Nicholas Hart; Marilyn Roberts-Harewood; Michelle Cummins; Moji Awogbade; Bernard Davis
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

Review 4.  Fluid replacement therapy for acute episodes of pain in people with sickle cell disease.

Authors:  Uduak Okomo; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

5.  Comparison of isotonic and hypotonic intravenous maintenance fluids: a randomized clinical trial.

Authors:  Jeremy N Friedman; Carolyn E Beck; Julie DeGroot; Denis F Geary; Daniel J Sklansky; Stephen B Freedman
Journal:  JAMA Pediatr       Date:  2015-05       Impact factor: 16.193

6.  The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database.

Authors:  Sophie Lanzkron; C Patrick Carroll; Carlton Haywood
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

7.  Normal saline is associated with increased sickle red cell stiffness and prolonged transit times in a microfluidic model of the capillary system.

Authors:  Marcus A Carden; Meredith Fay; Yumiko Sakurai; Brynn McFarland; Sydney Blanche; Caleb DiPrete; Clinton H Joiner; Todd Sulchek; Wilbur A Lam
Journal:  Microcirculation       Date:  2017-07       Impact factor: 2.628

Review 8.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

Review 9.  The history of 0.9% saline.

Authors:  Sherif Awad; Simon P Allison; Dileep N Lobo
Journal:  Clin Nutr       Date:  2008-03-03       Impact factor: 7.324

10.  Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion.

Authors:  Marcus A Carden; Meredith E Fay; Xinran Lu; Robert G Mannino; Yumiko Sakurai; Jordan C Ciciliano; Caroline E Hansen; Satheesh Chonat; Clinton H Joiner; David K Wood; Wilbur A Lam
Journal:  Blood       Date:  2017-10-04       Impact factor: 25.476

View more
  5 in total

1.  Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain.

Authors:  Claudia R Morris; Lou Ann S Brown; Michael Reynolds; Carlton D Dampier; Peter A Lane; Amanda Watt; Polly Kumari; Frank Harris; Shaminy Manoranjithan; Reshika D Mendis; Janet Figueroa; Sruti Shiva
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

2.  Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: A multicenter perspective.

Authors:  Chris A Rees; David C Brousseau; Fahd A Ahmad; Jonathan Bennett; Seema Bhatt; Amanda Bogie; Kathleen M Brown; T Charles Casper; Laura L Chapman; Corrie E Chumpitazi; Daniel M Cohen; Carlton Dampier; Angela M Ellison; Hartmut Grasemann; Robert W Hickey; Lewis L Hsu; Peter A Lane; Nitya Bakshi; Sara Leibovich; Prabhumallikarjun Patil; Elizabeth C Powell; Rachel Richards; Syana Sarnaik; Debra L Weiner; Claudia R Morris
Journal:  Am J Hematol       Date:  2022-09-05       Impact factor: 13.265

Review 3.  Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.

Authors:  Melissa Azul; Eudorah F Vital; Wilbur A Lam; David K Wood; Joan D Beckman
Journal:  Transl Res       Date:  2022-03-27       Impact factor: 10.171

Review 4.  Precision Medicine and Sickle Cell Disease.

Authors:  Sara El Hoss; Wassim El Nemer; David C Rees
Journal:  Hemasphere       Date:  2022-08-18

5.  Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis in sickle cell disease: incidence and risk factors.

Authors:  Aafke E Gaartman; Ajab K Sayedi; Jorn J Gerritsma; Tim R de Back; Charlotte F van Tuijn; Man Wai Tang; Harriët Heijboer; Koen de Heer; Bart J Biemond; Erfan Nur
Journal:  Br J Haematol       Date:  2021-07-15       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.